Pharmaceutical company demand heats up for Enable Injections' advanced large-volume wearable injectors for patient-focused biologics delivery
FOR IMMEDIATE RELEASE / PRURGENT
CINCINNATI, OH—January 9, 2018—Enable Injections, Inc., developer of the advanced enFuse™ large-volume wearable injectors (LVWI) platform for subcutaneous delivery of biologics, has named Dr. Jeannette “Jeannie” Joughin Executive Vice President and Chief Commercial Officer.
A global pharmaceutical executive and long-time champion of a patient-focused approach to treatment, Dr. Joughin joined the company as Vice President of Corporate Development in 2015. In her new role she will support the CEO and Board with investment strategy and remains responsible for business development, strategic pharma partnerships, alliance management, as well as aiding in selection and prioritization of Enable Injections’ global portfolio.
“Jeannie has exceptional experience and a proven track record of developing mutually-beneficial partnerships with pharmaceutical companies who share our passion for radically improving the patient infusion experience,” said Michael D. Hooven, Enable Injections’ President and CEO. “Today we are recognizing her leadership in helping to drive the next phase of growth for Enable Injections.”
Prior to joining Enable Injections, Dr. Joughin was Vice President, Business Development at drug maker CSL Behring, with global responsibility. . The Australian native also served as Marketing Manager at Mayne Pharma, as General Manager of Medimark International, and held clinical and commercial roles at Bristol-Myers Squibb.
About Enable Injections, Inc.
Founded by medical device industry veterans, Cincinnati, OH-based Enable Injections develops and manufactures wearable devices that allow easy, comfortable patient self-administration of large volume/high viscosity drugs in doses from 4 ml to 50 ml. The Enable body-worn enFuse™ drug delivery platform utilizes any standard container closure system, including syringes or vials; automatically warms and can automatically mix lyophilized solutions. Enable’s devices are available for pharmaceutical and biotechnology industry investigational use. For more information please visit www.enableinjections.com and follow us on www.twitter.com/EnableInjection.